Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery (LEADER7)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03739528|
Recruitment Status : Recruiting
First Posted : November 14, 2018
Last Update Posted : December 4, 2018
|Condition or disease||Intervention/treatment||Phase|
|Cataract||Drug: Levofloxacin + dexamethasone followed by dexamethasone Drug: Tobramycin + Dexamethasone||Phase 3|
In clinical practice, topical treatment following cataract surgery is frequently administered using a combination between an antibiotic and a corticosteroid to promote patient adherence to therapy and to obtain both prevention of infection and treatment of post-surgical inflammation.
The combination of tobramycin and dexamethasone is among the most widely used combinations, however, treatment duration and the need for tapering posology over several weeks may favour the development of bacterial resistance. The study treatment associating a broad-spectrum antibiotic with a highly effective corticosteroid that can be used for a short period of time (one week) is therefore of considerable interest.
The aim of this study is to evaluate the non-inferiority of the study treatment, used for a limited period of time and followed by dexamethasone alone, compared to standard treatment in preventing and treating ocular inflammation and in preventing post-operative infection while limiting the emergence of antibiotic resistance.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||800 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||A randomized, parallel-group study|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for an Additional 7 Days vs. Tobramycin + Dexamethasone for 14 Days for the Prevention and Treatment of Inflammation and Prevention of Infection Associated With Cataract Surgery in Adults - LEADER 7|
|Actual Study Start Date :||September 3, 2018|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||March 2019|
Experimental: Levofloxacin + Dexamethasone followed by dexamethasone
Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).
Drug: Levofloxacin + dexamethasone followed by dexamethasone
Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.
Other Name: Levofloxacin + dexamethasone followed by Maxidex
Active Comparator: Tobramycin + dexamethasone
Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).
Drug: Tobramycin + Dexamethasone
Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
Other Name: Tobradex
- Proportion of patients without signs of anterior chamber inflammation [ Time Frame: After 14 days of treatment ]The proportion of patients without signs of anterior chamber inflammation (sum of cells and flare score = 0). The following non-inferiority hypotheses will be tested: H0 : πT - πS ≤ - Δ; H1 : πT - πS > - Δ. Where πT and πS are the proportions of patients without signs of anterior chamber inflammation in the test and standard treatments, respectively, and the non-inferiority margin is Δ = 10%.
- Incidence of endophthalmitis [ Time Frame: After 3, 7 and 14 days of treatment ]The proportion of diagnoses of endophthalmitis after administration of study treatment in the study will be assessed and reported. Diagnosis of endophthalmitis is based on clinical evaluation of signs and symptoms (such as swollen eyelids, ocular pain, conjunctival hyperemia, decreased visual acuity, opaque vitreous) through slit lamp examination, and microbiological tests on conjunctival or corneal swabs.
- Proportion of patients without signs of anterior ocular chamber inflammation [ Time Frame: After 3 and 7 days of treatment ]The proportion of patients without signs of anterior chamber inflammation (sum of cells and flare score = 0). The following non-inferiority hypotheses will be tested: H0 : πT - πS ≤ - Δ; H1 : πT - πS > - Δ. Where πT and πS are the proportions of patients without signs of anterior chamber inflammation in the test and standard treatments, respectively, and the non-inferiority margin is Δ = 10%.
- Conjunctival hyperemia [ Time Frame: After 3, 7 and 14 days of treatment ]Conjunctival hyperemia will be evaluated with slit lamp and results provided as a score as follows: 0 = absence of inflammation, 1 = mild inflammation (some vessels injected), 2 = moderate inflammation (diffuse injection of vessels, but individual vessels are still discernable) 3 = severe inflammation (intense injection of vessels, individual vessels not easily discernable).
- Total Ocular Symptoms Score (TOSS) [ Time Frame: After 3, 7 and 14 days of treatment ]The TOSS is a patient-reported evaluation in the TOSS Questionnaire of 3 ocular symptoms: itching/burning, hyperemia of conjunctiva and tearing. Each symptom is given a score: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
- Ocular pain/discomfort: 4-point scale [ Time Frame: After 3, 7 and 14 days of treatment ]Overall ocular pain and discomfort will be evaluated by the subject on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).
- Use of rescue therapy [ Time Frame: After 3, 7 and 14 days of treatment ]All rescue therapy used following cataract surgery is to be reported at all visits.
- Intraocular pressure (IOP) [ Time Frame: At the Screening Visit, day 4, day 8 and day 15 ]IOP is measured using a tonometer. IOP is measured as mmHg; normal intraocular pressures average between 12-22 mm Hg.
- Visual acuity [ Time Frame: Measured on Day 15 ]Decrease in visual acuity assessed as per local clinical practice
- Adverse events [ Time Frame: From screening to Day 15 ]Adverse events will be described according to System Organ Classes (SOC) and Preferred Terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) and will be presented by treatment group.
- Global evaluation [ Time Frame: At day 4, day 8 and day 15 ]Global evaluation will be evaluated on a 4-point scale: 0 = no intolerability, 1 = mild intolerability, 2 = moderate intolerability, 3 = maximum intolerability.
- Burning, stinging, blurred vision [ Time Frame: At day 4, day 8 and day 15 ]Burning, stinging, blurred vision will be evaluated on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
- Assessment of patient diary (compliance) [ Time Frame: At day 4, day 8 and day 15 ]Compliance will be evaluated on Day 4, Day 8 and Day 15 by means of a patient diary in which the instillations are to be recorded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03739528
|Contact: Alessandro Colombo, Dr.||+39 02 4385 firstname.lastname@example.org|
|Contact: Francesco Bandello, Prof.||+39 02 email@example.com|
Show 57 Study Locations
|Principal Investigator:||Francesco Bandello, Prof.||Ospedale San Raffaele IRCCS S.r.l.|